Relay Therapeutics (RLAY) Net Income towards Common Stockholders (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$79.1 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 1.49% year-over-year to -$79.1 million in Q1 2026; TTM through Mar 2026 was -$262.4 million, a 64.77% increase from a year earlier, with the FY2025 full-year figure at -$756.2 million, up 1.75% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$79.1 million, down from -$35.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RLAY reached as high as -$35.1 million in Q4 2025 and fell as low as -$484.9 million in Q4 2024.
• Historically, Net Income towards Common Stockholders has averaged -$105.8 million across 5 years, with a median of -$82.7 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders plunged 443.15% in 2024 and surged 92.76% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$75.1 million in 2022, then dropped by 18.93% to -$89.3 million in 2023, then plunged by 443.15% to -$484.9 million in 2024, then jumped by 92.76% to -$35.1 million in 2025, then sank by 125.53% to -$79.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$79.1 million in Q1 2026, -$35.1 million in Q4 2025, and -$74.2 million in Q3 2025.